drugset / Trial / NCT07177235

Ketamine for the Treatment of Refractory Status Epilepticus

NCT07177235

Phase 4 Not yet recruiting 50 enrolled Thomas Jefferson University
RandomizedParallel-groupOpen-labelTreatment

Summary

This pilot feasibility study aims to examine how the timing of ketamine introduction as a third-line anti-seizure medication infusion relates to seizure cessation in patients with refractory status epilepticus (RSE).

Timeline

Start
2025-11
Primary completion
2027-07
Completion
2028-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketamine Small molecule Intravenous
Comparator Midazolam Small molecule

Indications